BIOMAX-INFORMATICS
7.4.2021 10:02:13 CEST | Business Wire | Press release
Biomax Informatics announces the launch of version 2.0 of AILANI. AILANI 2.0 represents an even more modern and user-friendly version of Biomax Informatics’ semantic search platform. Via the new AILANI Cloud Interface, users can quickly and cost-effectively search through numerous publicly accessible, academic full-text documents, news feeds, clinical studies, and COVID-19-relevant patents, receiving intelligent responses to their questions, alongside their keyword search. Unlike in the first version of AILANI, people using the AILANI Cloud benefit from a document tagging system for collaborative purposes, as well as from the introduction of “personas,” which enable a different experience for distinct user groups.
Through the new AILANI Enterprise solution, Biomax also offers customers the opportunity to integrate their own data – in both a structured and unstructured format – into the system, to expand the semantic search function to this data by means of AI algorithms, and to compare it with publicly accessible data. To increase acceptance among employees and to optimize integration into the system landscape, the portal can be quickly and easily adapted to the company’s corporate design. An optional group function (persona) enables the rapid exchange of data and responses within the team. This allows new ideas and new knowledge to be generated and shared more quickly. The time required for product development can be reduced considerably, decisions can be made more rapidly and in an enhanced manner, and competitive advantages can be realized.
“The experiences and feedback of our customers over the past year have shown us that we can make a valuable contribution to successful research and product development in the life sciences sector through AILANI,” says Dr. Sascha Losko, Director of Product Management. “With AILANI 2.0 and our new pricing model, we are also able to provide companies of any size with optimal access to our software.”
Through AILANI for COVID-19, Biomax Informatics began offering free access to AILANI back in spring 2020. Interested parties can try out AILANI for free at https://ailani.ai and get answers to specific questions relating to COVID-19.
Free Webinar about AILANI 2.0
Biomax will offer a free webinar on AILANI 2.0 at 3:00 p.m. on April 29, 2021. For more information, please visit our website at www.biomax.com/webinar or follow us on LinkedIn. Biomax experts are already looking forward to providing attendees with a detailed insight into AILANI 2.0.
About Biomax Informatics:
Biomax Informatics offers software solutions for better decision-making and optimal knowledge management in the life sciences industry. Using the company’s software, customers can generate added value through the integration of information from their own and public resources, enabling them to achieve a knowledge-based approach for the development of innovative life sciences products. Biomax’s global customers include clinics, companies, and research institutions successful in the fields of research into active substances, diagnostics, fine chemicals, and food and plant products. The company, which was founded in 1997 and currently has 45 members of staff, is headquartered in Planegg near Munich. Further information can be found at www.biomax.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom